Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined...
Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic application...
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondans...
Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endp...
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-...
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HUTCHMED (China) Lim...
Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health ...
Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, announced an agree...
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases...
Rebrand announced in June as part of Fujifilm Life Sciences Group restructuring becomes official FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences...
- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) announced that its TROP2-directed antibody-drug ...
- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater...
Market participants appear to be adopting a wait and watch stance, with sentiment shaped less by near term fundamentals and more by expecta...
© 2026 Biopharma Boardroom. All Rights Reserved.
